Non-Drug Costs Associated with Outpatient Infliximab Administration in Pediatric Inflammatory Bowel Disease

BACKGROUND Infliximab is the most widely used biologic agent for Crohn’s disease (CD) and ulcerative colitis (UC), but requires outpatient infusion units due to its intravenous administration requirement.